Courses

During this introduction to the science behind a wide variety of systemic treatments given to people with prostate, bladder, or kidney cancer, Dr Elaine Vickers will discuss current hormone therapies, immunotherapy and targeted treatments.

A focus on modern systemic treatments for non-small cell lung cancer (NSCLC) as well as the gene faults that drive many NSCLCs; the targeted treatments that exploit these faults, such as inhibitors of EGFR, ALK, ROS1, B-Raf, HER2, MET, and RET; the immune system and checkpoint inhibitor group of immunotherapies, including PD-1, PD-L1 and CTLA-4 targeted antibody therapies